UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2020
Commission File Number: 001-36515
Materialise NV
Technologielaan 15
3001 Leuven
Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This Form 6-K is incorporated by reference into the registrants Registration Statement on Form F-3 (File No. 333-213649).
First Quarter 2020 Financial Results
Except as otherwise required by the context, references to Materialise, Company, we, us and our are to Materialise NV and its subsidiaries.
First Quarter 2020 Results
Total revenue for the first quarter of 2020 decreased 1.8% to 46,245 kEUR compared to 47,115 kEUR for the first quarter of 2019.
Revenue from our Materialise Software segment increased 5.0% to 9,821 kEUR for the first quarter of 2020 from 9,350 kEUR for the same quarter last year.
Revenue from our Materialise Medical segment increased 15.3% to 15,645 kEUR for the first quarter of 2020 compared to 13,566 kEUR for the same period in 2019. Compared to the first quarter of 2019, revenues from medical devices and services grew 18.2% and revenues from our medical software grew 9.8%.
Revenue from our Materialise Manufacturing segment decreased 13.9% to 20,815 kEUR for the first quarter of 2020 from 24,184 kEUR for the first quarter of 2019.
Gross profit was 24,632 kEUR, or 53.3% of total revenue, for the first quarter of 2020 compared to 25,579 kEUR, or 54.3% of total revenue, for the first quarter of 2019.
Research and development (R&D), sales and marketing (S&M) and general and administrative (G&A) expenses increased, in the aggregate, 3.9% to 26,351 kEUR for the first quarter of 2020 from 25,361 kEUR for the first quarter of 2019.
Net other operating income was 683 kEUR compared to 1,258 kEUR for the first quarter of 2019.
Operating result decreased to (1,037) kEUR from 1,476 kEUR for the first quarter of 2019.
Net financial result was (1,321) kEUR compared to (592) kEUR for the first quarter of 2019. The share in loss of joint venture amounted to (39) kEUR compared to (123) kEUR for the same period in 2019.
The first quarter of 2020 contained income tax expenses of (457) kEUR, compared to (1,065) kEUR in the first quarter of 2019.
As a result of the above, net loss for the first quarter of 2020 was (2,853) kEUR, compared to (304) kEUR for the same period in 2019. Total comprehensive income for the first quarter of 2020, which includes exchange differences on translation of foreign operations, was (6,996) kEUR compared to 284 kEUR for the 2019 period.
Adjusted EBITDA decreased to 3,603 kEUR from 5,827 kEUR. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the first quarter of 2020 was 7.8% compared to 12.4% for the first quarter of 2019.
Segment EBITDA from our Materialise Software segment decreased to 2,645 kEUR from 2,961 kEUR while the segment EBITDA margin (segment EBITDA divided by segment revenue) was 26.9% compared to 31.7% for the prior-year period.
Segment EBITDA from our Materialise Medical segment increased to 2,455 kEUR compared to 1,773 kEUR while the segment EBITDA margin was 15.7% compared to 13.1% for the first quarter of 2019.
Segment EBITDA from our Materialise Manufacturing segment decreased to 1,118 kEUR from 3,695 kEUR while the segment EBITDA margin was 5.4% compared to 15.3% for the first quarter of 2019.
At March 31, 2020, we had cash and equivalents of 127,135 kEUR compared to 128,897 kEUR at December 31, 2019. Gross debt amounted to 124,702 kEUR, compared to 127,939 kEUR at December 31, 2019. As a result, our net cash position increased 1,474 kEUR during the first quarter of 2020.
Cash flow from operating activities for the first quarter of 2020 was 7,273 kEUR compared to 4,081 kEUR for the same period in 2019. Total capital expenditures for the first quarter of 2020 amounted to 3,053 kEUR.
Net shareholders equity at March 31, 2020 was 135,679 kEUR compared to 142,675 kEUR at December 31, 2019.
Non-IFRS Measures
Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding non-cash stock-based compensation expenses and acquisition-related expenses of business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the Companys day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the Companys business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The Company believes that these measurements are useful to measure a companys ability to grow or as a valuation measurement. The Companys calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The Companys presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
Exchange Rate
This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.104309, the reference rate of the European Central Bank on March 31, 2020.
About Materialise
Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialises open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest 3D printing facilities in the world.
Consolidated income statements (Unaudited)
For the three months ended March 31, |
For the three months ended March 31, |
|||||||||||||||||||
In 000 | 2020 | 2020 | 2019 | 2020 | 2019 | |||||||||||||||
U.S.$ | | | | | ||||||||||||||||
Revenue |
51,069 | 46,245 | 47,155 | 46,245 | 47,115 | |||||||||||||||
Cost of sales |
(23,867 | ) | (21,613 | ) | (21,536 | ) | (21,613 | ) | (21,536 | ) | ||||||||||
Gross profit |
27,201 | 24,632 | 25,579 | 24,632 | 25,579 | |||||||||||||||
Gross profit as % of revenue |
53.3 | % | 53.3 | % | 54.3 | % | 53.3 | % | 54.3 | % | ||||||||||
Research and development expenses |
(7,208 | ) | (6,527 | ) | (5,686 | ) | (6,527 | ) | (5,686 | ) | ||||||||||
Sales and marketing expenses |
(13,945 | ) | (12,627 | ) | (12,079 | ) | (12,627 | ) | (12,079 | ) | ||||||||||
General and administrative expenses |
(7,948 | ) | (7,197 | ) | (7,596 | ) | (7,197 | ) | (7,596 | ) | ||||||||||
Net other operating income (expenses) |
754 | 683 | 1,258 | 683 | 1,258 | |||||||||||||||
Operating (loss) profit |
(1,145 | ) | (1,037 | ) | 1,476 | (1,037 | ) | 1,476 | ||||||||||||
Financial expenses |
(2,011 | ) | (1,821 | ) | (1,196 | ) | (1,821 | ) | (1,196 | ) | ||||||||||
Financial income |
552 | 500 | 604 | 500 | 604 | |||||||||||||||
Share in loss of joint venture |
(43 | ) | (39 | ) | (123 | ) | (39 | ) | (123 | ) | ||||||||||
(Loss) profit before taxes |
(2,646 | ) | (2,396 | ) | 761 | (2,396 | ) | 761 | ||||||||||||
Income taxes |
(505 | ) | (457 | ) | (1,065 | ) | (457 | ) | (1,065 | ) | ||||||||||
Net (loss) profit for the period |
(3,151 | ) | (2,853 | ) | (304 | ) | (2,853 | ) | (304 | ) | ||||||||||
Net (loss) profit attributable to: |
||||||||||||||||||||
The owners of the parent |
(3,100 | ) | (2,807 | ) | (304 | ) | (2,807 | ) | (304 | ) | ||||||||||
Non-controlling interest |
(51 | ) | (47 | ) | | (47 | ) | | ||||||||||||
Earnings per share attributable to owners of the parent |
|
|||||||||||||||||||
Basic |
(0.06 | ) | (0.05 | ) | (0.01 | ) | (0.05 | ) | (0.01 | ) | ||||||||||
Diluted |
(0.06 | ) | (0.05 | ) | (0.01 | ) | (0.05 | ) | (0.01 | ) | ||||||||||
Weighted average basic shares outstanding |
53,173 | 53,173 | 52,891 | 53,173 | 52,891 | |||||||||||||||
Weighted average diluted shares outstanding |
53,173 | 53,173 | 52,891 | 53,173 | 52,891 |
Consolidated statements of comprehensive income (Unaudited)
For the three months ended March 31, |
For the three months ended March 31, |
|||||||||||||||||||
In 000 | 2020 | 2020 | 2019 | 2020 | 2019 | |||||||||||||||
U.S.$ | | | | | ||||||||||||||||
Net profit (loss) for the period |
(3,151 | ) | (2,853 | ) | (304 | ) | (2,853 | ) | (304 | ) | ||||||||||
Other comprehensive income |
||||||||||||||||||||
Exchange difference on translation of foreign operations |
(4.575 | ) | (4,143 | ) | 588 | (4,143 | ) | 588 | ||||||||||||
Other comprehensive income (loss), net of taxes |
(4,575 | ) | (4,143 | ) | 588 | (4,143 | ) | 588 | ||||||||||||
Total comprehensive income (loss) for the year, net of taxes |
(7,726 | ) | (6,996 | ) | 284 | (6,996 | ) | 284 | ||||||||||||
Total comprehensive income (loss) attributable to: |
||||||||||||||||||||
The owners of the parent |
(6,997 | ) | (6,336 | ) | 284 | (6,336 | ) | 284 | ||||||||||||
Non-controlling interest |
(729 | ) | (660 | ) | | (660 | ) | |
Consolidated statement of financial position (Unaudited)
As of March 31, |
As of December 31, |
|||||||
In 000 | 2020 | 2019 | ||||||
| | |||||||
Assets |
||||||||
Non-current assets |
||||||||
Goodwill |
19,424 | 20,174 | ||||||
Intangible assets |
26,092 | 27,395 | ||||||
Property, plant & equipment |
88,682 | 90,331 | ||||||
Right-of-Use assets |
10,057 | 10,586 | ||||||
Investments in joint ventures |
| 39 | ||||||
Deferred tax assets |
257 | 192 | ||||||
Other non-current assets |
10,053 | 9,391 | ||||||
Total non-current assets |
154,565 | 158,108 | ||||||
Current assets |
||||||||
Inventories |
12,674 | 12,696 | ||||||
Trade receivables |
37,174 | 40,322 | ||||||
Other current assets |
10,080 | 9,271 | ||||||
Cash and cash equivalents |
127,135 | 128,897 | ||||||
Total current assets |
187,063 | 191,186 | ||||||
Total assets |
341,628 | 349,294 |
As of March 31, |
As of December 31, |
|||||||
In 000 | 2020 | 2019 | ||||||
| | |||||||
Equity and liabilities |
||||||||
Equity |
||||||||
Share capital |
3,066 | 3,066 | ||||||
Share premium |
138,090 | 138,090 | ||||||
Consolidated reserves |
(3,007 | ) | (195 | ) | ||||
Other comprehensive income |
(4,918 | ) | (1.394 | ) | ||||
Equity attributable to the owners of the parent |
133,231 | 139,567 | ||||||
Non-controlling interest |
2,447 | 3,107 | ||||||
Total equity |
135,679 | 142,675 | ||||||
Non-current liabilities |
||||||||
Loans & borrowings |
100,999 | 104,673 | ||||||
Lease liabilities |
6,510 | 6,427 | ||||||
Deferred tax liabilities |
5,906 | 5,747 | ||||||
Deferred income |
5,418 | 5,031 | ||||||
Other non-current liabilities |
584 | 696 | ||||||
Total non-current liabilities |
119,418 | 122,575 | ||||||
Current liabilities |
||||||||
Loans & borrowings |
13,821 | 13,389 | ||||||
Lease liabilities |
3,372 | 3,449 | ||||||
Trade payables |
18,166 | 18,516 | ||||||
Tax payables |
3,048 | 3,363 | ||||||
Deferred income |
29,471 | 27,641 | ||||||
Other current liabilities |
18,653 | 17,686 | ||||||
Total current liabilities |
86,531 | 84,044 | ||||||
Total equity and liabilities |
341,628 | 349,294 |
Consolidated statement of cash flows (Unaudited)
For the three months ended March 31, | ||||||||
in 000 | 2020 | 2019 | ||||||
| | |||||||
Operating activities |
||||||||
Net (loss) profit for the period |
(2,853 | ) | (304 | ) | ||||
Non-cash and operational adjustments |
||||||||
Depreciation of property, plant & equipment |
3,600 | 3,429 | ||||||
Amortization of intangible assets |
1,115 | 1,101 | ||||||
Share-based payment expense |
(75 | ) | (177 | ) | ||||
Loss (gain) on disposal of property, plant & equipment |
16 | 51 | ||||||
Movement in provisions |
(3 | ) | 14 | |||||
Movement reserve for bad debt |
221 | (136 | ) | |||||
Financial income |
(500 | ) | (60 | ) | ||||
Financial expense |
1,821 | 583 | ||||||
Impact of foreign currencies |
83 | |||||||
Share in loss of a joint venture (equity method) |
39 | 124 | ||||||
(Deferred) income taxes |
454 | 1,065 | ||||||
Other |
147 | 35 | ||||||
Working capital adjustment & income tax paid |
||||||||
Decrease (increase) in trade receivables and other receivables |
1,582 | (2,393 | ) | |||||
Decrease (increase) in inventories |
(3 | ) | (1,200 | ) | ||||
Increase (decrease) in trade payables and other payables |
2,300 | 2,251 | ||||||
Income tax paid |
(588 | ) | (385 | ) | ||||
Net cash flow from operating activities |
7,273 | 4,081 |
For the three months ended March 31, | ||||||||
in 000 | 2020 | 2019 | ||||||
| | |||||||
Investing activities |
||||||||
Purchase of property, plant & equipment |
(2,575 | ) | (2,657 | ) | ||||
Purchase of intangible assets |
(478 | ) | (575 | ) | ||||
Proceeds from the sale of property, plant & equipment & intangible assets |
69 | | ||||||
Convertible loan to third party |
(300 | ) | (2,500 | ) | ||||
Investments in joint-ventures |
| | ||||||
Interest received |
| 53 | ||||||
Net cash flow used in investing activities |
(3,284 | ) | (5,679 | ) | ||||
Financing activities |
||||||||
Proceeds from loans & borrowings |
1,500 | |||||||
Repayment of loans & borrowings |
(2,585 | ) | (2,543 | ) | ||||
Repayment of finance leases |
(1,016 | ) | (1,399 | ) | ||||
Interest paid |
(634 | ) | (503 | ) | ||||
Other financial income (expense) |
(138 | ) | (110 | ) | ||||
Net cash flow from (used in) financing activities |
(4,373 | ) | (3,055 | ) | ||||
Net increase of cash & cash equivalents |
(383 | ) | (4,653 | ) | ||||
Cash & cash equivalents at beginning of the year |
128,897 | 115,506 | ||||||
Exchange rate differences on cash & cash equivalents |
(1,379 | ) | 199 | |||||
Cash & cash equivalents at end of the year |
127,135 | 111,052 |
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)
For the three months ended March 31, |
For the three months ended March 31, |
|||||||||||||||
In 000 | 2020 | 2019 | 2020 | 2019 | ||||||||||||
| | | | |||||||||||||
Net profit (loss) for the period |
(2,853 | ) | (304 | ) | (2,853 | ) | (304 | ) | ||||||||
Income taxes |
457 | 1,065 | 457 | 1,065 | ||||||||||||
Financial expenses |
1,821 | 1,196 | 1,821 | 1,196 | ||||||||||||
Financial income |
(500 | ) | (604 | ) | (500 | ) | (604 | |||||||||
Share in loss of joint venture |
39 | 123 | 39 | 123 | ||||||||||||
Depreciation and amortization |
4,715 | 4,530 | 4,715 | 4,530 | ||||||||||||
EBITDA |
3,678 | 6,006 | 3,678 | 6,006 | ||||||||||||
Non-cash stock-based compensation expense (1) |
(75 | ) | (177 | ) | (75 | ) | (177 | ) | ||||||||
Acquisition-related expenses business combinations |
| | | | ||||||||||||
ADJUSTED EBITDA |
3,603 | 5,829 | 3,603 | 5,829 |
(1) | Non-cash share-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees. |
Segment P&L (Unaudited)
In 000 | Materialise Software |
Materialise Medical |
Materialise Manufacturing |
Total segments |
Unallocated (1)(2) |
Consolidated | ||||||||||||||||||
| | | | | | |||||||||||||||||||
For the three months ended March 31, 2020 |
||||||||||||||||||||||||
Revenues |
9,821 | 15,645 | 20,815 | 46,281 | (36 | ) | 46,245 | |||||||||||||||||
Segment adjusted EBITDA |
2,645 | 2,455 | 1,118 | 6,218 | (2,615 | ) | 3,603 | |||||||||||||||||
Segment adjusted EBITDA % |
26.9 | % | 15.7 | % | 5.4 | % | 13.4 | % | 7.8 | % | ||||||||||||||
For the three months ended March 31, 2019 |
||||||||||||||||||||||||
Revenues |
9,350 | 13,566 | 24,184 | 47,100 | 15 | 47,115 | ||||||||||||||||||
Segment adjusted EBITDA |
2,961 | 1,773 | 3,695 | 8,429 | (2,600 | ) | 5,829 | |||||||||||||||||
Segment adjusted EBITDA % |
31.7 | % | 13.1 | % | 15.3 | % | 17.9 | % | 12.4 | % |
(1) | Unallocated Revenues consist of occasional one-off sales by our core competencies not allocated to any of our segments. |
(2) | Unallocated segment EBITDA consists of corporate research and development, corporate headquarter costs and other operating income (expense), and the added non-cash share-based compensation expenses and acquisition related expenses of business combinations that are included in Adjusted EBITDA. |
Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited)
For the three months ended March 31, |
For the three months ended March 31, |
|||||||||||||||
In 000 | 2020 | 2019 | 2020 | 2019 | ||||||||||||
| | | | |||||||||||||
Net profit (loss) for the period |
(2,853 | ) | (304 | ) | (2,853 | ) | (304 | ) | ||||||||
Income taxes |
457 | 1,065 | 457 | 1,065 | ||||||||||||
Financial cost |
1,821 | 1,196 | 1,821 | 1,196 | ||||||||||||
Financial income |
(500 | ) | (604 | ) | (500 | ) | (604 | ) | ||||||||
Share in loss of joint venture |
39 | 123 | 39 | 123 | ||||||||||||
Operating profit |
(1,037 | ) | 1,476 | (1,037 | ) | 1,476 | ||||||||||
Depreciation and amortization |
4,715 | 4,530 | 4,715 | 4,530 | ||||||||||||
Corporate research and development |
747 | 464 | 747 | 464 | ||||||||||||
Corporate headquarter costs |
2,368 | 2,565 | 2,368 | 2,565 | ||||||||||||
Other operating (income) expense |
(575 | ) | (606 | ) | (575 | ) | (606 | ) | ||||||||
Segment EBITDA |
6,218 | 8,429 | 6,218 | 8,429 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MATERIALISE NV | ||
By: |
/s/ Wilfried Vancraen | |
| ||
Name: |
Wilfried Vancraen | |
Title: |
Chief Executive Officer |
Date: April 30, 2020